TY - JOUR
T1 - A pre-post study of vitamin d supplement effects on urinary megalin
T2 - The emerging predictive role of megalin in diabetic nephropathy progression
AU - Kasabri, Violet
AU - Akour, Amal
AU - Bulatova, Nailya
AU - Suyagh, Maysa
AU - Yousef, Al Motassem
AU - Al Hawari, Hussein
AU - Al Shelleh, Sameeha
AU - Bzour, Jameel
AU - Fahmawi, Hiba
N1 - Publisher Copyright:
© 2020 Bentham Science Publisher.
PY - 2020
Y1 - 2020
N2 - Introduction: Megalin is a renal proximal tubular protein that reabsorbs vitamin D from glomerular filtrates. Previous studies found significantly higher levels of urinary megalin in chronic microvascular complications of diabetes with associated metabolic derangements. This study aimed at testing the effect of vitamin D supplements on urinary megalin levels in diabetic nephropathy (DN) patients with vitamin D hypovitaminosis. Methods: Sixty-three participants with vitamin D deficiency and diabetic nephropathy (DN) were en-rolled in the pre-post study; urinary megalin levels with various clinical parameters and serum levels of vitamin D3 were measured and compared to the baseline at 3-and 6-month intervals. Results: Interestingly, a supplementation related increase in serum vitamin D3 levels at 3-and 6-month interventions affected a constellation of ameliorations in the DN progression of clinical and metabolic factors. There was a decrease in ACR with a concomitant decrease in urinary megalin and a decrease in blood pressure, fasting plasma glucose (FPG), and low-density lipoprotein – cholesterol (LDL-C) – but an increase in glomerular filtration rate (GFR). Principally, pellet urinary megalin associated positively (p < 0.05) with vitamin D hypovitaminosis and the albumin-to-creatinine ratio (ACR) but negatively (p < 0.05) with Ca2+ and body mass index (BMI). Conclusion: Vitamin D supplementation could elucidate underlying pathophysiological mechanisms and a prognostic significance of urinary megalin association with DN, obesity/MetS-related dyslipide-mia, and hyperglycemia modification. Megalin is a putative sensitive and precise predictive marker and an emerging therapeutic target of renal anomalies.
AB - Introduction: Megalin is a renal proximal tubular protein that reabsorbs vitamin D from glomerular filtrates. Previous studies found significantly higher levels of urinary megalin in chronic microvascular complications of diabetes with associated metabolic derangements. This study aimed at testing the effect of vitamin D supplements on urinary megalin levels in diabetic nephropathy (DN) patients with vitamin D hypovitaminosis. Methods: Sixty-three participants with vitamin D deficiency and diabetic nephropathy (DN) were en-rolled in the pre-post study; urinary megalin levels with various clinical parameters and serum levels of vitamin D3 were measured and compared to the baseline at 3-and 6-month intervals. Results: Interestingly, a supplementation related increase in serum vitamin D3 levels at 3-and 6-month interventions affected a constellation of ameliorations in the DN progression of clinical and metabolic factors. There was a decrease in ACR with a concomitant decrease in urinary megalin and a decrease in blood pressure, fasting plasma glucose (FPG), and low-density lipoprotein – cholesterol (LDL-C) – but an increase in glomerular filtration rate (GFR). Principally, pellet urinary megalin associated positively (p < 0.05) with vitamin D hypovitaminosis and the albumin-to-creatinine ratio (ACR) but negatively (p < 0.05) with Ca2+ and body mass index (BMI). Conclusion: Vitamin D supplementation could elucidate underlying pathophysiological mechanisms and a prognostic significance of urinary megalin association with DN, obesity/MetS-related dyslipide-mia, and hyperglycemia modification. Megalin is a putative sensitive and precise predictive marker and an emerging therapeutic target of renal anomalies.
KW - Albumin-to-creatinine ratio
KW - Diabetes mellitus type 2
KW - Diabetic nephropathy
KW - Glomerular filtration rate
KW - Megalin
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85092127558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092127558&partnerID=8YFLogxK
U2 - 10.2174/1871530320666200525012811
DO - 10.2174/1871530320666200525012811
M3 - Article
C2 - 32448110
AN - SCOPUS:85092127558
SN - 1871-5303
VL - 20
SP - 1552
EP - 1557
JO - Endocrine, Metabolic and Immune Disorders - Drug Targets
JF - Endocrine, Metabolic and Immune Disorders - Drug Targets
IS - 9
ER -